Floatz logo

16 assets in Anaplastic Oligodendroglioma

Therapeutic assets addressing Anaplastic Oligodendroglioma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cediranib
Anaplastic Oligodendroglioma
National Cancer Institute (NCI)P2BBB (73)
Irinotecan
Anaplastic Oligodendroglioma
City of Hope Medical CenterP2BB (70)
Trametinib
Anaplastic Oligodendroglioma
Novartis PharmaceuticalsP4BB (69)
Carboplatin
Anaplastic Oligodendroglioma
Oliver JonasP2BB (67)
Dabrafenib
Anaplastic Oligodendroglioma
Novartis PharmaceuticalsP4BB (65)
Sargramostim
Anaplastic Oligodendroglioma
Children's Oncology GroupP1CCC (52)
Eflornithine
Anaplastic Oligodendroglioma
Mayo ClinicP1/2CCC (48)
Retifanlimab
Anaplastic Oligodendroglioma
Mayo ClinicP1/2CCC (48)
5-ala
Anaplastic Oligodendroglioma
Universität MünsterP1CC (47)
Abexinostat
Anaplastic Oligodendroglioma
University of NebraskaP1CC (43)
Carboxylesterase-Expressing Allogeneic Neural Stem Cells
Anaplastic Oligodendroglioma
City of Hope Medical CenterP1CC (43)
Cyclophosphamide
Anaplastic Oligodendroglioma
Dana-Farber Cancer InstituteP1CC (43)
Onc 206
Anaplastic Oligodendroglioma
Jazz PharmaceuticalsP1CC (43)
Rqnestin
Anaplastic Oligodendroglioma
Dana-Farber Cancer InstituteP1CC (43)
Survaxm
Anaplastic Oligodendroglioma
Children's Oncology GroupP1CC (43)
Vorinostat
Anaplastic Oligodendroglioma
National Cancer Institute (NCI)P1CC (43)